Answers are grounded in this paper and cite their sources.
Although once a severe and often fatal illness, myasthenia gravis can now be well managed with several relatively safe and effective therapies. Management involves a graded approach, beginning with cholinesterase inhibitors for mild symptoms and advancing to immunomodulating medications for more severe weakness. There are several immunomodulating agents from which to choose; selection is based largely on time to clinical effect and adverse effects. This review will discuss the selection and use of therapies for patients with myasthenia gravis.
No takes yet. Share an insight, caveat, or question.
Saperstein et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: